VEGFA and anthrax infection: vascular endothelial growth factor (VEGF), erythropoietin, Human IgG αPA83, hGAD65, immunotoxin αCD22-PE40, Plasmodium surface proteins (AMS1, MSP1, VP28, Pfs25, Pfs28, CtxB-Pfs25 and Pfs 48/45), Anti-CD-22-gelonin, lsc αHSV glycoprotein D, CSFV-E2, hTRAIL, and Anti-PA 83 anthrax IgG1, which possess therapeutical applications in anemia treatment, wound healing, anti-malarial vaccines, and as an antibody against anthrax, Herpes simplex virus, human papillomavirus, and foot-and-mouth disease [10,53,54].